HINGHAM, Mass., Nov. 17, 2020 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (NASDAQ:MBOT) announced that it has received patents in multiple jurisdictions, further demonstrating the Company's continued execution of expanding and protecting its Intellectual Property (IP) portfolio. The Company now has 40 issued/allowed patents and 23 patent applications pending worldwide.
"As we continue to make progress on the development, clinical and regulatory fronts, it is encouraging that we are also achieving our goals to broaden the protection of our novel technologies," commented Harel Gadot, CEO, President and Chairman. "Strengthening our IP portfolio is a critical component of Microbot's strategy for facilitating product evolution and maximizing future commercial opportunities."
The U.S. Patent and Trademark Office (USPTO) issued a Notice of Allowance 684 pertaining to the Company's Self-Cleaning Shunt (SCS) device. The allowed patent application is a Continuation of a patent, issued on July 19, 2016, and covers a device for mitigating occlusion in an implantable catheter. The claims are directed to a device comprising a tube having at least one drainage opening disposed in its wall and configured for implantation within a body cavity, further comprising a cleaning element having at least one cleaning protrusion extending into the opening and configured to move within the opening.
Additionally, the European Patent Office (EPO) granted an EP Patent covering the Company's guidewire technology for use with endo-luminal interventions, and related to the Company's LIBERTYTM development. This is the second European patent granted for this unique technology and extends protection to include the device's current development, having a double guidewire comprising a first hollow guidewire and a second guidewire deployed within the first guidewire, and an adjuster mechanism operable to displace the second guidewire longitudinally relative to the first guidewire between at least three states.